ADCT Quote, Financials, Valuation and Earnings

Addex Therapeutics has a net margin of -167.59% compared to ADC Therapeutics SA's net margin of -2841.85%. ADC Therapeutics SA's return on equity of -- beat Addex Therapeutics's return on equity of 91.08%.

ADC Therapeutics SA has a consensus price target of $8.20, signalling upside risk potential of 144.78%. On the other hand Addex Therapeutics has an analysts' consensus of $30.00 which suggests that it could grow by 233.33%. Given that Addex Therapeutics has higher upside potential than ADC Therapeutics SA, analysts believe Addex Therapeutics is more attractive than ADC Therapeutics SA.

ADC Therapeutics SA has a beta of 1.895, which suggesting that the stock is 89.492% more volatile than S&P 500. In comparison Addex Therapeutics has a beta of 1.646, suggesting its more volatile than the S&P 500 by 64.6%.

ADC Therapeutics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Addex Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADC Therapeutics SA pays -- of its earnings as a dividend. Addex Therapeutics pays out -- of its earnings as a dividend.

ADC Therapeutics SA quarterly revenues are $23M, which are larger than Addex Therapeutics quarterly revenues of $62.3K. ADC Therapeutics SA's net income of -$38.6M is lower than Addex Therapeutics's net income of -$1.6M. Notably, ADC Therapeutics SA's price-to-earnings ratio is -- while Addex Therapeutics's PE ratio is 1.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADC Therapeutics SA is 4.56x versus 24.63x for Addex Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CRISPR Therapeutics AG has a net margin of -167.59% compared to ADC Therapeutics SA's net margin of -106.6%. ADC Therapeutics SA's return on equity of -- beat CRISPR Therapeutics AG's return on equity of -18.65%.

ADC Therapeutics SA has a consensus price target of $8.20, signalling upside risk potential of 144.78%. On the other hand CRISPR Therapeutics AG has an analysts' consensus of $81.80 which suggests that it could grow by 44.98%. Given that ADC Therapeutics SA has higher upside potential than CRISPR Therapeutics AG, analysts believe ADC Therapeutics SA is more attractive than CRISPR Therapeutics AG.

ADC Therapeutics SA has a beta of 1.895, which suggesting that the stock is 89.492% more volatile than S&P 500. In comparison CRISPR Therapeutics AG has a beta of 1.822, suggesting its more volatile than the S&P 500 by 82.156%.

ADC Therapeutics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CRISPR Therapeutics AG offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADC Therapeutics SA pays -- of its earnings as a dividend. CRISPR Therapeutics AG pays out -- of its earnings as a dividend.

ADC Therapeutics SA quarterly revenues are $23M, which are smaller than CRISPR Therapeutics AG quarterly revenues of $35M. ADC Therapeutics SA's net income of -$38.6M is higher than CRISPR Therapeutics AG's net income of -$136M. Notably, ADC Therapeutics SA's price-to-earnings ratio is -- while CRISPR Therapeutics AG's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADC Therapeutics SA is 4.56x versus -- for CRISPR Therapeutics AG. Usually stocks with elevated PS ratios are considered overvalued.

NLS Pharmaceutics has a net margin of -167.59% compared to ADC Therapeutics SA's net margin of --. ADC Therapeutics SA's return on equity of -- beat NLS Pharmaceutics's return on equity of --.

ADC Therapeutics SA has a consensus price target of $8.20, signalling upside risk potential of 144.78%. On the other hand NLS Pharmaceutics has an analysts' consensus of -- which suggests that it could grow by 11167.61%. Given that NLS Pharmaceutics has higher upside potential than ADC Therapeutics SA, analysts believe NLS Pharmaceutics is more attractive than ADC Therapeutics SA.

ADC Therapeutics SA has a beta of 1.895, which suggesting that the stock is 89.492% more volatile than S&P 500. In comparison NLS Pharmaceutics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

ADC Therapeutics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NLS Pharmaceutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADC Therapeutics SA pays -- of its earnings as a dividend. NLS Pharmaceutics pays out -- of its earnings as a dividend.

ADC Therapeutics SA quarterly revenues are $23M, which are larger than NLS Pharmaceutics quarterly revenues of --. ADC Therapeutics SA's net income of -$38.6M is higher than NLS Pharmaceutics's net income of --. Notably, ADC Therapeutics SA's price-to-earnings ratio is -- while NLS Pharmaceutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADC Therapeutics SA is 4.56x versus -- for NLS Pharmaceutics. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines has a net margin of -167.59% compared to ADC Therapeutics SA's net margin of 0.11%. ADC Therapeutics SA's return on equity of -- beat BeOne Medicines's return on equity of -11.54%.

ADC Therapeutics SA has a consensus price target of $8.20, signalling upside risk potential of 144.78%. On the other hand BeOne Medicines has an analysts' consensus of $330.95 which suggests that it could grow by 31.26%. Given that ADC Therapeutics SA has higher upside potential than BeOne Medicines, analysts believe ADC Therapeutics SA is more attractive than BeOne Medicines.

ADC Therapeutics SA has a beta of 1.895, which suggesting that the stock is 89.492% more volatile than S&P 500. In comparison BeOne Medicines has a beta of 0.282, suggesting its less volatile than the S&P 500 by 71.823%.

ADC Therapeutics SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADC Therapeutics SA pays -- of its earnings as a dividend. BeOne Medicines pays out -- of its earnings as a dividend.

ADC Therapeutics SA quarterly revenues are $23M, which are smaller than BeOne Medicines quarterly revenues of $1.1B. ADC Therapeutics SA's net income of -$38.6M is lower than BeOne Medicines's net income of $1.3M. Notably, ADC Therapeutics SA's price-to-earnings ratio is -- while BeOne Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADC Therapeutics SA is 4.56x versus 6.47x for BeOne Medicines. Usually stocks with elevated PS ratios are considered overvalued.